![Placeholder Image Placeholder Image](https://prod1.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehoben
-
Media ReleaseNovartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
-
Media ReleaseNovartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
-
Media ReleaseAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
-
Media ReleaseAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
-
Media ReleaseFDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis stellt neue Leiterin der Pharmaceuticals Business Unit vor
-
Media ReleaseNovartis announces new leader of Pharmaceuticals Business Unit
-
Media ReleaseNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
-
Media ReleaseNovartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
-
Media ReleaseNovartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
-
Media ReleaseNovartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Pagination
- ‹ Previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- …
- 16
- › Next page